Universal Beteiligungs und Servicegesellschaft mbH Purchases Shares of 127,994 IQVIA Holdings Inc. (NYSE:IQV)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 127,994 shares of the medical research company's stock, valued at approximately $25,152,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of IQVIA as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. raised its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA during the 4th quarter worth approximately $60,000. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Truist Financial reduced their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res lowered shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. UBS Group cut their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.

IQVIA Stock Performance

Shares of IQV stock traded down $0.86 during trading hours on Friday, hitting $140.16. The company's stock had a trading volume of 2,874,682 shares, compared to its average volume of 1,578,625. The company has a 50 day moving average of $150.79 and a 200 day moving average of $180.93. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The stock has a market cap of $24.25 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company's revenue was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $2.54 earnings per share. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.